Display options
Cite
Lee JO, Kim JW, Kang HJ, et al. Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder. Clin Psychopharmacol Neurosci. 2018;16(4):461-468doi: 10.9758/cpn.2018.16.4.461.
Lee, J. O., Kim, J. W., Kang, H. J., Hong, J. P., & Kim, J. M. (2018). Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 16(4), 461-468. https://doi.org/10.9758/cpn.2018.16.4.461
Lee, Jeong-Ok, et al. "Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 16,4 (2018): 461-468. doi: https://doi.org/10.9758/cpn.2018.16.4.461
Lee JO, Kim JW, Kang HJ, Hong JP, Kim JM. Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder. Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):461-468. doi: 10.9758/cpn.2018.16.4.461. PMID: 30466218; PMCID: PMC6245296.
Copy Download .nbib Format: NLM
Share it on

Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):461-468. doi: 10.9758/cpn.2018.16.4.461.

Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Jeong-Ok Lee, Ju-Wan Kim, Hee-Ju Kang, Jin-Pyo Hong, Jae-Min Kim

Affiliations

  1. Department of Psychiatry, Naju National Hospital, Naju, Korea.
  2. Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea.
  3. Department of Psychiatry, Sungkyunkwan University School of Medicine, Seoul, Korea.

PMID: 30466218 PMCID: PMC6245296 DOI: 10.9758/cpn.2018.16.4.461

Abstract

OBJECTIVE: Cognitive disturbance is one of the major symptoms of depression and may be improved by treatment with antidepressants. This study aimed to investigate the predictors of cognitive improvement in patients with major depressive disorder (MDD) who were taking antidepressants.

METHODS: This study included 86 patients with MDD who completed 12 weeks of antidepressant monotherapy. Cognitive symptoms were assessed using the Perceived Deficits Questionnaire-Korean version (PDQ-K), which addresses four domains of cognitive functioning (attention/concentration, retrospective memory, prospective memory, and organization/planning) and was administered at study entry and at the 12-week end point. A variety of demographic, clinical, and treatment-related variables were evaluated as predictors of changes in total and domain scores.

RESULTS: All PDQ-K domains showed significant improvement after 12 weeks of antidepressant treatment. More severe initial depressive symptoms, fewer sick-leave days at study entry, and reduced use of concomitant anxiolytics/hypnotics during treatment were significantly associated with greater cognitive improvement.

CONCLUSION: Cognitive symptoms are more responsive to antidepressant treatment in patients with severe MDD. Reduced use of anxiolytics and hypnotics could improve the cognitive functioning of patients with MDD taking antidepressants.

Keywords: Anti-anxiety agents; Antidepressive agents; Cognition; Depression; Prediction

References

  1. J Affect Disord. 2012 Feb;136(3):1017-26 - PubMed
  2. J Clin Psychiatry. 2014 Aug;75(8):864-76 - PubMed
  3. J Affect Disord. 1998 Sep;50(2-3):97-108 - PubMed
  4. J Occup Rehabil. 2008 Mar;18(1):27-34 - PubMed
  5. JAMA. 2003 Jun 18;289(23):3095-105 - PubMed
  6. J Clin Psychiatry. 2013;74 Suppl 2:14-8 - PubMed
  7. Int J Psychiatry Med. 1997;27(2):93-105 - PubMed
  8. J Clin Psychiatry. 2014 Dec;75(12):1359-70 - PubMed
  9. Clin Interv Aging. 2017 May 11;12:773-783 - PubMed
  10. Int J Neuropsychopharmacol. 2015 Jul 25;19(2):null - PubMed
  11. J Affect Disord. 2009 Dec;119(1-3):1-8 - PubMed
  12. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57 - PubMed
  13. JAMA. 2003 Jun 18;289(23):3135-44 - PubMed
  14. Int J Technol Assess Health Care. 2011 Oct;27(4):369-75 - PubMed
  15. Int J Neuropsychopharmacol. 2014 Oct;17(10):1557-67 - PubMed
  16. Health Policy. 1990 Dec;16(3):199-208 - PubMed
  17. Neuropsychopharmacology. 2015 Jul;40(8):2025-37 - PubMed
  18. Clin Psychopharmacol Neurosci. 2016 Feb 29;14(1):26-32 - PubMed
  19. Arch Phys Med Rehabil. 2012 Oct;93(10):1774-81 - PubMed
  20. Br J Psychiatry. 1979 Apr;134:382-9 - PubMed
  21. Psychiatry Res. 2011 Aug 30;189(1):82-90 - PubMed
  22. Compr Psychiatry. 2016 Jul;68:24-33 - PubMed
  23. Psychiatry Res. 2006 Nov 29;145(1):39-48 - PubMed
  24. Clin Psychopharmacol Neurosci. 2016 Nov 30;14(4):378-382 - PubMed
  25. J Appl Physiol (1985). 2006 Oct;101(4):1237-42 - PubMed
  26. Am J Psychiatry. 2007 Jun;164(6):900-9 - PubMed
  27. Neuropsychopharmacology. 2002 Aug;27(2):260-9 - PubMed
  28. Lancet. 2007 Sep 8;370(9590):851-8 - PubMed
  29. Clin Drug Investig. 2012 Jun 1;32(6):373-85 - PubMed
  30. Psychiatry Res. 2014 Dec 15;220(1-2):245-50 - PubMed
  31. Can J Psychiatry. 2010 Oct;55(10):653-61 - PubMed
  32. Clin Psychopharmacol Neurosci. 2016 Feb 29;14(1):1-16 - PubMed
  33. CNS Drugs. 2004;18(1):37-48 - PubMed

Publication Types